Published in Transplant Proc on October 01, 1996
Intestinal transplantation in children with chronic intestinal pseudo-obstruction. Gut (1999) 1.52
Pre-emptive Intestinal Transplant: The Surgeon's Point of View. Dig Dis Sci (2017) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Cyclic vomiting syndrome in adults. Neurogastroenterol Motil (2008) 2.40
Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg (1987) 2.11
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05
Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet (1989) 2.01
Low flow venovenous bypasses in small dogs and pediatric patients undergoing replacement of the liver. Surg Gynecol Obstet (1986) 2.00
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Analysis of donor criteria for the prediction of outcome in clinical liver transplantation. Transplant Proc (1987) 1.90
Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg (1988) 1.89
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Endotoxaemia, pulmonary complications, and thrombocytopenia in liver transplantation. Lancet (1989) 1.82
Corrective treatment and anatomic considerations for laparoscopic cholecystectomy injuries. J Am Coll Surg (1994) 1.81
A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant (2009) 1.81
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80
Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78
Effect of the anesthetics benzyl alcohol and chloroform on bilayers made from monolayers. Biophys J (1979) 1.78
Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Factors in the Development of Liver Transplantation. Transplant Proc (1985) 1.74
Small intestinal transplantation in humans with or without the colon. Transplantation (1994) 1.74
Hepatic artery in liver transplantation. Transplant Proc (1987) 1.73
Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg (1998) 1.72
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71
Effect of cold ischemia time on the early outcome of human hepatic allografts preserved with UW solution. Transplantation (1991) 1.71
Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. Transplant Proc (1990) 1.71
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab (1997) 1.68
Hepatic artery thrombosis after pediatric liver transplantation--a medical or surgical event? Transplantation (1989) 1.67
Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J (2000) 1.66
Nonadherence consensus conference summary report. Am J Transplant (2009) 1.61